Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic editing of pathogenic TNNI3 mutation in restrictive cardiomyopathy rescues diastolic dysfunction of human induced pluripotent stem cell-derived cardiomyocytes

ABSTRACT: Genomic editing of pathogenic TNNI3 mutation in restrictive cardiomyopathy rescues diastolic dysfunction of human induced pluripotent stem cell-derived cardiomyocytes

PROVIDER: PRJNA1005230 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25630453.fastq.gz	Fastqsanger.gz
	SRR25630454.fastq.gz	Fastqsanger.gz
	SRR25630455.fastq.gz	Fastqsanger.gz
	SRR25630456.fastq.gz	Fastqsanger.gz
	SRR25630457.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Genomic editing of pathogenic TNNI3 mutation in restrictive cardiomyopathy rescues diastolic dysfunction of human induced pluripotent stem cell-derived cardiomyocytes

Project description:To investigate the physiological characteristics of cardiomyocytes (CM) in restrictive cardiomyopathy (RCM), we established RCM(heterozygous)-iPSC and produced RCM(homozygous)-iPSC and corrected Isogenic-iPSC using CRISPER-CAS9 technology. Then, we used the RNA-seq data obtained from these three iPSCs and three different healthy iPSC-derived CMs for gene expression profiling analysis.

2023-08-21 | GSE240775 | GEO

Pediatric Restrictive Cardiomyopathy Mutation Analysis

Project description:Pediatric Restrictive Cardiomyopathy Mutation Analysis

| PRJNA1197576 | ENA

Pediatric Restrictive Cardiomyopathy Mutation Analysis

Project description:Pediatric Restrictive Cardiomyopathy Mutation Analysis

| PRJNA1197578 | ENA

Therapeutic base editing alleviates restrictive cardiomyopathy

Project description:Restrictive cardiomyopathy (RCM) is a severe cardiac disorder characterized by impaired ventricular filling and diastolic dysfunction, with mutations in sarcomeric proteins representing major causative factors. Mutations of TNNI3 gene (e.g. p.R192H) constitute major genetic causes of RCM, particularly affecting pediatric patients and being associated with poor prognosis. Here, we demonstrate that adenine base editor (ABE) is able effectively correct RCM-causing mutation and alleviate RCM in a murine model. We first developed a novel murine model harboring the Tnni3R193H mutation that recapitulates the hallmark features of human RCM. Importantly, targeted delivery of ABE via adeno-associated virus (AAV) achieved efficient and precise correction of the Tnni3R193H mutation in adult RCM mice, leading to significant improvement of cardiac functions. Our findings establish base editing as a therapeutic strategy for RCM and highlight its broader potential for treating genetic cardiomyopathies in clinical settings.

2025-04-30 | GSE295799 | GEO

Therapeutic base editing alleviates restrictive cardiomyopathy

Project description:Therapeutic base editing alleviates restrictive cardiomyopathy

| PRJNA1256393 | ENA

Precise genomic editing of a pathogenic RBM20 mutation rescues dilated cardiomyopathy

Project description:Precise genomic editing of a pathogenic RBM20 mutation rescues dilated cardiomyopathy

| PRJNA868596 | ENA

Precise genomic editing of a pathogenic RBM20 mutation rescues dilated cardiomyopathy

Project description:Precise genomic editing of a pathogenic RBM20 mutation rescues dilated cardiomyopathy

| PRJNA867480 | ENA

Pathogenic variants in PRDM16 impair cardiomyocytes maturation and cause cardiomyopathy phenotypes in humans

Project description:Loss of the PR domain 16 (PRDM16) genetic locus has been suggested as the needed trigger for the development of left ventricular non-compaction cardiomyopathy (LVNC) and dilated cardiomyopathy (DCM) in patients with 1p36 deletion syndrome. Furthermore, lack of Prdm16 in the murine heart has recently been shown to cause a spectrum of cardiomyopathy phenotypes. In spite of these advances, our understanding of the downstream transcriptional pathways regulated by PRDM16 that lead to these cardiac phenotypes is limited. OBJECTIVE: to unveil the downstream transcriptional pathways involved in the development of cardiomyopathy phenotypes associated with PRDM16 mutations/deletion in human and mice. METHODS AND RESULTS: We hypothesized that PRDM16 acts as an upstream regulator of key transcriptional pathways involved in cardiac maturation. Induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from a patient with a PRDM16 variant, cardiac tissue from mice expressing the human variant, mice with cardiac-specific deletion of Prdm16 and in vitro gain and loss of Prdm16 function were employed. Here we show that de novo pathogenic variants in PRDM16 are sufficient to cause LVNC in humans. In contrast, haploinsufficiency or complete deletion of Prdm16 in cardiomyocytes in mice led to pathological hypertrophy and dilated cardiomyopathy respectively. We demonstrated that PRDM16 regulates cardiac maturation through the maintenance of estrogen-related receptors (ERRs) expression. By contrast, PRDM16 acts as a supressor of transforming growth factor beta (TGFB) signaling. CONCLUSIONS: PRDM16 is a novel regulator of cardiac maturation acting upstream of ERRs and their regulators, and a suppressor of fibrotic signaling including TGFB.

2023-12-01 | GSE193877 | GEO

Pathogenic variants in PRDM16 impair cardiomyocytes maturation and cause cardiomyopathy phenotypes in mice

2023-12-01 | GSE193873 | GEO

Title Page Cardiac Gene Therapy Rescues Diabetic Cardiomyopathy and Lowers Blood Glucose

Project description:Diabetic cardiomyopathy, an increasingly global epidemic and a major cause of heart failure with preserved ejection fraction (HFpEF), is associated with hyperglycemia, insulin resistance, and intra-cardiomyocyte calcium mishandling. Here we identify that, in db/db mice with type 2 diabetes induced HFpEF, abnormal remodeling of cardiomyocyte transverse-tubule microdomains occurs with downregulation of the membrane scaffolding protein cardiac bridging integrator 1 (cBIN1). Transduction of cBIN1 by AAV9 gene therapy can restore transverse-tubule microdomains to normalize intracellular distribution of calcium handling proteins and, surprisingly, glucose transporter 4 (GLUT4). Cardiac proteomics revealed that AAV9-cBIN1 normalizes components of calcium handling and GLUT4 translocation machineries. Functional studies further identified that AAV9-cBIN1 normalizes insulin-dependent glucose uptake in diabetic cardiomyocytes. Phenotypically, AAV9-cBIN1 rescues cardiac lusitropy, improves exercise intolerance, and ameliorates hyperglycemia in diabetic mice. Restoration of transverse-tubule microdomains can improve cardiac function in the setting of diabetic cardiomyopathy, and also improve systemic glycemic control.

2023-10-24 | PXD044236 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data